Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Net Income (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Net Income for 7 consecutive years, with -$23.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 49.03% year-over-year to -$23.5 million, compared with a TTM value of $87.0 million through Dec 2025, up 146.44%, and an annual FY2025 reading of $87.0 million, up 146.44% over the prior year.
  • Net Income was -$23.5 million for Q4 2025 at Keros Therapeutics, down from -$7.3 million in the prior quarter.
  • Across five years, Net Income topped out at $148.5 million in Q1 2025 and bottomed at -$53.0 million in Q3 2024.
  • Average Net Income over 5 years is -$21.7 million, with a median of -$28.5 million recorded in 2022.
  • The sharpest move saw Net Income crashed 328.21% in 2022, then surged 444.32% in 2025.
  • Year by year, Net Income stood at -$6.9 million in 2021, then plummeted by 328.21% to -$29.7 million in 2022, then crashed by 56.32% to -$46.5 million in 2023, then grew by 0.92% to -$46.0 million in 2024, then surged by 49.03% to -$23.5 million in 2025.
  • Business Quant data shows Net Income for KROS at -$23.5 million in Q4 2025, -$7.3 million in Q3 2025, and -$30.7 million in Q2 2025.